Related Experiment Videos
Combination chemotherapy for disseminated malignant melanoma
1Wilford Hall Medical Center/PSMH, Lackland AFB, TX 78236-5300, USA.
Abstract:
Malignant melanoma, once disseminated, is associated with very short survival times and has proven highly resistant to systemic therapy. Although many chemotherapeutic agents can produce small response rates in these patients, the most consistent responses occur with dacarbazine (DTIC). Numerous combination regimens, with and without DTIC, have been tested against disseminated melanoma, with varying and inconsistent outcomes. The most encouraging results have occurred with the combination of DTIC, cisplatin, BCNU and tamoxifen. The use of high-dose chemotherapy with and without autologous bone marrow support and the addition of biologic agents such as inteferon-alpha and interleukin-2 to conventional chemotherapy have also been actively investigated. This paper reviews the various approaches taken against disseminated melanoma employing systemic chemotherapy.
Insights
Systemic chemotherapy for advanced malignant melanoma shows limited efficacy. Dacarbazine (DTIC) offers consistent responses, with combination regimens showing varied outcomes, necessitating further research.
Area of Science:
- Oncology
- Medical Research
Background:
- Malignant melanoma is a highly aggressive cancer with poor prognosis once disseminated.
- Systemic therapies for advanced melanoma have historically shown limited success and high resistance.
Purpose of the Study:
- To review systemic chemotherapy approaches for disseminated malignant melanoma.
- To evaluate the efficacy of various chemotherapeutic agents and combination regimens.
Main Methods:
- Review of existing literature on systemic chemotherapy for metastatic melanoma.
- Analysis of treatment outcomes for dacarbazine (DTIC) and combination therapies.
- Investigation of high-dose chemotherapy and biologic agent integration.
Main Results:
- Dacarbazine (DTIC) demonstrates the most consistent response rates among single agents.
- Combination regimens, notably DTIC, cisplatin, BCNU, and tamoxifen, show encouraging results.
- High-dose chemotherapy and biologic agents like interferon-alpha and interleukin-2 are under investigation.
Conclusions:
- Systemic chemotherapy for disseminated melanoma presents significant challenges due to resistance.
- Combination therapies and novel approaches require further investigation to improve patient survival and outcomes.